Patheon

Wesley P. Wheeler has been appointed chief executive officer of Patheon Inc., effective December 10, 2007. Mr. Wheeler will succeed Riccardo Trecroce, who plans to leave the company in 2008, following a transition period.

“With Patheon’s restructuring initiatives well underway, we are focused on taking the company forward to the next phase of growth and profitability,” said Ramsey Frank, managing director of JLL Partners, the company’s largest shareholder, and chairman of Patheon Inc.’s corporate governance committee. “Wes Wheeler is a highly experienced pharmaceutical executive with a proven record of leading successful, international businesses. His in-depth knowledge of the industry and breadth of pharmaceutical experience will serve Patheon well as we move forward to grow and deliver improved value to our stakeholders.”

“We would like to thank Riccardo Trecroce for his commitment and contributions to Patheon over his seven years with the Company,” said Peter Green, chairman of Patheon’s board of directors. “Riccardo led Patheon through a particularly challenging time in its evolution, successfully recapitalizing the company earlier this year and launching restructuring and operational initiatives to improve the Company’s profitability. We thank him for his dedication and wish him every success in his future endeavours.”

Mr. Wheeler has 29 years of multinational experience in pharmaceutical manufacturing, sales and marketing, R&D and engineering, with three global pharmaceutical companies. He joins the company from Valeant Pharmaceuticals International, where he served most recently as president, North America, R&D and global manufacturing. Prior to joining Valeant in 2003, he served as president and chief executive officer of DSM Pharmaceuticals, Inc., where he led the company through a business turnaround, significantly increasing new business, compliance and profitability in approximately 13 months. Prior to DSM, Mr. Wheeler was senior vice president of logistics and strategy for GlaxoSmithKline, where he was responsible for managing the manufacturing rationalization of Glaxo Wellcome and SmithKline Beecham. He also served as vice president of marketing for Glaxo Wellcome, responsible for antibiotic, antiviral, gastrointestinal and metabolic products as well as developing the marketing services infrastructure for the company.